PFIZER INC. for PFIZER INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 19, 2011 | $3,550,000 | Replaced |
| 2nd Quarter - Amendment | May 18, 2012 | $3,610,000 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Trans Pacific Partnership Negotiations Japan Market Access and Regulatory Issues US-Korea Free Trade Agreement Israel Patent Issues Brazil IP - WTO Case Australian FTA Implementation Chile IP Issues - FTA Implementation
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH DAMOND | — |
Taxation/Internal Revenue Code TAX
Repatriation Deferral Deferral for active-financing income- extension S. 1203, R& D Tax Credit Extension and Enhancement H.R. 422, R&D Tax Credit Extension and Enhancement H.R. 2098, CFC Look Through Extension H.R. 1834, Freedom to Invest Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARIA CINO | — |
| KEN W COLE | — |
| JENNIFER DUCK | — |
| ANTHONY PRINCIPI | — |
| CAROLINE MOODY SCHELLHAS New | — |
Health Issues HCR
Health Care Reform Comparative Effectiveness Research Prescription Drug User Fee Act (PDUFA) Follow on Biologics Antibiotic Incentives Tax Extenders Antimicrobial Resistance Strategies to Address Antimicrobial Resistance Senate Labor - HHS Appropriations bill, with regard to funding of the 317 Program H.R. 965, The Preservation of Antibiotics for Medical Treatment Act, 2011 H.R. 979, FEHBP Priscription Drug Integrity, Transparency and Cost Savings Act, 2011 S. 668, Health Care Bureacrats Elimination Act, 2011 S. 1094, Combating Autism Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEN W COLE | — |
| JENNIFER DUCK | — |
| JOHN PAUL HALLIWELL | — |
| LOUIS A LAMARCA | — |
| ANGELA WALKER RIEMER | — |
| MARY BRIDGET WALSH | — |
| JENNIFER SWENSON WALTON | — |
Consumer Issues/Safety/Products CSP
Importation Certified Importer Program Dextromethorphan Distribution Dextromethorphan Abuse Reduction The Food, Drug and Cosmetic Globalization Act ELDU Ban on Cephalosporin PSE Issues OTC Products in Flexible Spending Account H.R. 741, Act to Prohibit the Marketing of Authorized Generic Drugs, 2011 S. 373, Fair Prescription Drug Competition Act, 2011
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN PAUL HALLIWELL | — |
| JENNIFER SWENSON WALTON | — |
Copyright/Patent/Trademark CPT
Counterfeit Pharmaceuticals Expert Patent Courts Pilot Programs Patent Settlements Patent Reform Act, 2011 Protecting Consumer Access to Generic Drugs S. 27, Preserve Access to Affordable Generics S.23, America Invents Act, 2011 H.R. 1249, America Invents Act, 2011
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEN W COLE | — |
| JENNIFER DUCK | — |
| JOHN PAUL HALLIWELL | — |
| ANGELA WALKER RIEMER | — |
| MARY BRIDGET WALSH | — |
| JENNIFER SWENSON WALTON | — |
Medicare/Medicaid MMM
Medicare Prescription Drug Benefit Medicare Rebates Medicare Coverage Medicare Part D Average Manufacturer Price Regulation Patient Protection and Affordable Care Act Implementation Debt Ceiling and Part D H.R. 452, Medicare Decision Accountability Act, 2011 S. 1206, Medicare Drug savings Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEN W COLE | — |
| JENNIFER DUCK | — |
| JOHN PAUL HALLIWELL | — |
| ANGELA WALKER RIEMER | — |
| MARY BRIDGET WALSH | — |
| JENNIFER SWENSON WALTON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.